Milk whey contains bioactive proteins capable to inhibit osteoclast formation and bone resorption

Bone ◽  
2012 ◽  
Vol 50 ◽  
pp. S89
Author(s):  
J. Walli⁎ ◽  
K.G. Büki ◽  
V. Nieminen-Pihala ◽  
J. Saarimäki ◽  
K. Väänänen ◽  
...  
Bone ◽  
2007 ◽  
Vol 41 (5) ◽  
pp. 745-751 ◽  
Author(s):  
S. Djien Tan ◽  
Teun J. de Vries ◽  
Anne Marie Kuijpers-Jagtman ◽  
Cornelis M. Semeins ◽  
Vincent Everts ◽  
...  

2015 ◽  
Vol 16 (11) ◽  
pp. 26599-26607 ◽  
Author(s):  
Shengnan Qin ◽  
Estabelle Ang ◽  
Libing Dai ◽  
Xiaohong Yang ◽  
Dongping Ye ◽  
...  

2020 ◽  
Author(s):  
Ramkumar Thiyagarajan ◽  
Maria Rodríguez-Gonzalez ◽  
Catherine Zaw ◽  
Kenneth Ladd Seldeen ◽  
Mireya Hernandez ◽  
...  

Abstract Background: Osteoclastic bone resorption markedly increases with aging, leading to osteoporosis characterized by weak and fragile bones. Mice exhibit greater bone resorption and poor bone mass when Sirt1 is removed from their osteoclasts. Here we investigated the ex vivo impacts of putative Sirt1 activators, resveratrol (RSV), SRT2183 and SRT1720, on osteoclast formation and activity in primary mouse bone marrow cells (BMCs) derived from wild type (WT) and osteoclast specific Sirt1 knockout (OC-Sirt1KO) mice and in the RAW264.7 mouse macrophage cell line. Results: We found that SRT2183 and SRT1720 inhibit formation of osteoclasts and actin belts in both BMCs and RAW264.7 cells, whereas RSV does not. We also observed that the OC-Sirt1KO mice exhibited less bone mineral density, and the BMCs harvested from these mice yielded more osteoclasts than BMCs harvested from littermate controls. Interestingly, both SRT2183 and SRT1720 reduced osteoclast and actin belt formation in BMCs from OC-Sirt1KO mice. SRT2183 and SRT1720 also significantly disrupted actin belts of mature osteoclasts from WT mice BMCs, within 3 and 6 hours of administration. Furthermore, these compounds inhibited resorption activity of mature osteoclasts, while RSV did not. Conclusion: Our findings suggest SRT2183 and SRT1720 impede bone resorption by disrupting actin belts of mature osteoclasts, inhibit actin belt formation, and inhibit osteoclastogenesis even in the absence of Sirt1. Thus, further understanding the mechanism of action of these compounds may pave the way for potential new therapies in alleviating osteoporosis associated bone loss.


2014 ◽  
Vol 21 (5) ◽  
pp. 641-649 ◽  
Author(s):  
B. Tian ◽  
A. Qin ◽  
Z.Y. Shao ◽  
T. Jiang ◽  
Z.J. Zhai ◽  
...  

Molecules ◽  
2021 ◽  
Vol 26 (7) ◽  
pp. 1982
Author(s):  
Wataru Ariyoshi ◽  
Shiika Hara ◽  
Ayaka Koga ◽  
Yoshie Nagai-Yoshioka ◽  
Ryota Yamasaki

Although the anti-tumor and anti-infective properties of β-glucans have been well-discussed, their role in bone metabolism has not been reviewed so far. This review discusses the biological effects of β-glucans on bone metabolisms, especially on bone-resorbing osteoclasts, which are differentiated from hematopoietic precursors. Multiple immunoreceptors that can recognize β-glucans were reported to be expressed in osteoclast precursors. Coordinated co-stimulatory signals mediated by these immunoreceptors are important for the regulation of osteoclastogenesis and bone remodeling. Curdlan from the bacterium Alcaligenes faecalis negatively regulates osteoclast differentiation in vitro by affecting both the osteoclast precursors and osteoclast-supporting cells. We also showed that laminarin, lichenan, and glucan from baker’s yeast, as well as β-1,3-glucan from Euglema gracilisas, inhibit the osteoclast formation in bone marrow cells. Consistent with these findings, systemic and local administration of β-glucan derived from Aureobasidium pullulans and Saccharomyces cerevisiae suppressed bone resorption in vivo. However, zymosan derived from S. cerevisiae stimulated the bone resorption activity and is widely used to induce arthritis in animal models. Additional research concerning the relationship between the molecular structure of β-glucan and its effect on osteoclastic bone resorption will be beneficial for the development of novel treatment strategies for bone-related diseases.


Bone Reports ◽  
2021 ◽  
Vol 14 ◽  
pp. 100865
Author(s):  
B.K. Davies ◽  
Andrew Hibbert ◽  
Mark Hopkinson ◽  
Gill Holdsworth ◽  
Isabel Orriss

2012 ◽  
Vol 113 (3) ◽  
pp. 946-955 ◽  
Author(s):  
Estabelle S. M. Ang ◽  
Nathan J. Pavlos ◽  
Shek Man Chim ◽  
Hao Tian Feng ◽  
Robin M. Scaife ◽  
...  

1993 ◽  
Vol 53 (3) ◽  
pp. 206-209 ◽  
Author(s):  
Kohei Notoya ◽  
Keiji Yoshida ◽  
Shigehisa Taketomi ◽  
Iwao Yamazaki ◽  
Masayoshi Kumegawa

Sign in / Sign up

Export Citation Format

Share Document